Cardinal Health, Inc.

Cardinal Health, Inc. is a global healthcare services and products company that plays a significant role in providing pharmaceutical and medical supplies to the U.S. federal government. The company leverages its extensive distribution network and expertise to deliver a wide range of products, including prescription medications, over-the-counter drugs, vaccines, radiopharmaceuticals, and other medical consumables to various government agencies. Cardinal Health's primary federal customers include the Department of Defense (DoD), Department of Veterans Affairs (VA), and National Institutes of Health (NIH). As a major player in the healthcare industry, Cardinal Health has been registered to receive federal awards since June 2001, demonstrating a long-standing relationship with government procurement.

Through its prime federal contract awards, Cardinal Health has consistently provided pharmaceutical distribution services under the Defense Logistics Agency's (DLA) Pharmaceutical Prime Vendor program. This program supplies a comprehensive range of medical products to military treatment facilities and deployed troops worldwide. The company has received numerous delivery orders for various pharmaceutical products, including antibiotics, pain medications, vaccines, and specialty drugs. Notable examples include the supply of Sirturo (Bedaquiline) tablets to the NIH Clinical Center, LYMPHOSEEK DOSE radiopharmaceuticals to the VA, and various medications to the Federal Correctional Complex Coleman. Cardinal Health also holds contracts with the VA for the delivery of radiopharmaceuticals used in medical imaging procedures, showcasing its capability to handle both standard pharmaceutical distribution and specialized medical products with strict handling requirements. These contracts are typically firm fixed-price delivery orders or purchase orders, with no set-aside designations, reflecting Cardinal Health's status as a large, for-profit corporation.

Cardinal Health's involvement in federal grant sub-awards appears to be limited based on the provided information. The only sub-grant award mentioned is related to the distribution of naloxone under a COVID-19 supplemental grant awarded to the Tennessee Department of Mental Health & Substance Abuse Services. This suggests that while Cardinal Health's primary focus is on federal contracts, the company does occasionally participate in grant-funded programs, particularly those related to public health initiatives and emergency response efforts. The naloxone distribution program highlights Cardinal Health's ability to support critical public health interventions through its extensive pharmaceutical distribution network.

Cardinal Health holds a significant indefinite delivery contract (IDV) with the Department of Veterans Affairs Veterans Health Administration. This single-award contract, valued at $773,677.24, is specifically for the provision of radiopharmaceutical products to support medical imaging procedures within the VA healthcare system. The contract, awarded on February 22, 2022, with a base period through February 21, 2023, includes a $983,677.24 firm fixed-price delivery order for radiopharmaceuticals covering the period from January 18, 2022, to January 18, 2023. This IDV highlights Cardinal Health's specialized capabilities in handling and distributing time-sensitive, radioactive medical products crucial for diagnostic imaging in VA medical facilities. The contract's structure allows the VA to ensure a reliable supply of these essential but short-lived medical tracers, supporting its mission to provide comprehensive healthcare services to veterans. Additionally, Cardinal Health's subsidiary, The Harvard Drug Group, L.L.C., secured a single-award IDC valued at $10,056,938.10 with the VA National Acquisition Center for the supply of Lurasidone Hydrochloride tablets, further demonstrating the company's ability to manage large-scale, multi-agency pharmaceutical supply agreements.